CA2638804C - Modified antibodies with enhanced biological activities - Google Patents

Modified antibodies with enhanced biological activities Download PDF

Info

Publication number
CA2638804C
CA2638804C CA2638804A CA2638804A CA2638804C CA 2638804 C CA2638804 C CA 2638804C CA 2638804 A CA2638804 A CA 2638804A CA 2638804 A CA2638804 A CA 2638804A CA 2638804 C CA2638804 C CA 2638804C
Authority
CA
Canada
Prior art keywords
ser
val
lys
pro
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2638804A
Other languages
English (en)
French (fr)
Other versions
CA2638804A1 (en
Inventor
Yasuhiko Masuho
Hiroaki Nagashima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
KM Biologics Co Ltd
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken, Teijin Pharma Ltd filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Publication of CA2638804A1 publication Critical patent/CA2638804A1/en
Application granted granted Critical
Publication of CA2638804C publication Critical patent/CA2638804C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2638804A 2006-03-03 2007-03-02 Modified antibodies with enhanced biological activities Expired - Fee Related CA2638804C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006057475 2006-03-03
JP2006-057475 2006-03-03
PCT/JP2007/054018 WO2007100083A1 (ja) 2006-03-03 2007-03-02 生物活性を強化した抗体改変体

Publications (2)

Publication Number Publication Date
CA2638804A1 CA2638804A1 (en) 2007-09-07
CA2638804C true CA2638804C (en) 2017-02-28

Family

ID=38459178

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2638804A Expired - Fee Related CA2638804C (en) 2006-03-03 2007-03-02 Modified antibodies with enhanced biological activities

Country Status (6)

Country Link
US (2) US20090304715A1 (cg-RX-API-DMAC10.html)
EP (2) EP2610268A1 (cg-RX-API-DMAC10.html)
JP (2) JP5598894B2 (cg-RX-API-DMAC10.html)
CA (1) CA2638804C (cg-RX-API-DMAC10.html)
ES (1) ES2602439T3 (cg-RX-API-DMAC10.html)
WO (1) WO2007100083A1 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304715A1 (en) * 2006-03-03 2009-12-10 Tokyo University Of Science Modified antibodies with enhanced biological activities
SI2185589T1 (sl) 2007-06-01 2016-04-29 University Of Maryland Baltimore Vezavna sredstva za Fc receptor konstantne regije imunoglobulina
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
WO2010065578A2 (en) * 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
WO2012002562A1 (en) * 2010-06-30 2012-01-05 Tokyo University Of Science Educational Foundation Administrative Organization Modified protein therapeutics
WO2012016073A2 (en) 2010-07-28 2012-02-02 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
JP5768147B2 (ja) 2011-02-28 2015-08-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 一価抗原結合タンパク質
WO2012116926A1 (en) * 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
CN104955839A (zh) 2013-01-28 2015-09-30 株式会社伊贝克 对人偏肺病毒具有特异性的人抗体或其抗原结合性片段
US10519194B2 (en) 2013-07-12 2019-12-31 Merck Patent Gmbh Removal of fragments from a sample containing a target protein using activated carbon
ES2935274T3 (es) * 2014-12-05 2023-03-03 Merck Patent Gmbh Anticuerpo con intercambio de dominios
IL309260B2 (en) 2015-07-24 2025-01-01 Gliknik Inc Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
US11466093B2 (en) 2015-07-27 2022-10-11 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
BR112019009484A2 (pt) 2016-12-09 2019-07-30 Gliknik Inc otimização de fabricação de gl-2045, um stradomer multimerizador
BR112019009495A2 (pt) 2016-12-09 2019-08-06 Gliknik Inc métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes
US20200040084A1 (en) * 2017-01-06 2020-02-06 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
WO2020014429A2 (en) * 2018-07-11 2020-01-16 Kurtagic Elma Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
KR20240137083A (ko) 2022-01-28 2024-09-19 에베크 인코포레이티드 변이주 교차성을 갖는 항SARS-CoV-2 인간 중화 항체 및 그의 항원 결합성 단편

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8824869D0 (en) 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
DE3908834A1 (de) 1989-03-17 1990-09-20 Hollingsworth Gmbh Vorrichtung zur ausscheidung von verunreinigungen eines faserverbandes an einer karde
CA2437958C (en) * 2001-03-09 2018-10-30 University Of Chicago Polymeric immunoglobulin fusion proteins that target low-affinity fc.gamma.receptors
CA2832136C (en) * 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
CA2553883C (en) * 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
US20090304715A1 (en) * 2006-03-03 2009-12-10 Tokyo University Of Science Modified antibodies with enhanced biological activities

Also Published As

Publication number Publication date
EP2006305A4 (en) 2010-06-30
EP2610268A1 (en) 2013-07-03
US20190367630A1 (en) 2019-12-05
US20090304715A1 (en) 2009-12-10
CA2638804A1 (en) 2007-09-07
JP5598894B2 (ja) 2014-10-01
EP2006305B1 (en) 2016-08-10
JP2012136519A (ja) 2012-07-19
JP5901299B2 (ja) 2016-04-06
JPWO2007100083A1 (ja) 2009-07-23
EP2006305A2 (en) 2008-12-24
EP2006305A9 (en) 2009-07-15
WO2007100083A1 (ja) 2007-09-07
ES2602439T3 (es) 2017-02-21

Similar Documents

Publication Publication Date Title
US20230340160A1 (en) Bispecific t cell activating antigen binding molecules
KR102890653B1 (ko) 항-cd33 항체, 항-cd33/항-cd3 이중특이성 항체, 및 이의 용도
CN112159469B (zh) 冠状病毒的抗体或其抗原结合片段
KR102444614B1 (ko) 프로테아제-활성화된 t 세포 이중특이적 분자
CN114751989B (zh) 包含三聚体tnf家族配体的抗原结合分子
KR102445255B1 (ko) 에리불린-기반 항체-약물 콘주게이트 및 사용 방법
KR20150122761A (ko) Ｔ 세포 활성화 항원 결합 분자
CN113646328B (zh) 一种免疫细胞因子及其制备与用途
CN110300766B (zh) 新型重组双功能融合蛋白及其制备方法和用途
US20090304715A1 (en) Modified antibodies with enhanced biological activities
EA032828B1 (ru) Иммунотерапевтические средства против комплекса tcr
KR20220120586A (ko) 에리불린 기반의 항체-약물 컨쥬게이트의 생성 방법
CN109536476A (zh) 具备透明质酸酶活性的靶向融合蛋白、制备方法及用途
US20020058311A1 (en) Chimeric leptin fused to immunoglobulin domain and use
RU2840013C1 (ru) Способ получения конъюгата антитело-лекарственное средство на основе эрибулина
RU2830288C2 (ru) Активируемые протеазой связывающие т-клетки биспецифические молекулы
HK40069172B (en) Antigen binding molecules comprising a trimeric tnf family ligand
HK40069172A (en) Antigen binding molecules comprising a trimeric tnf family ligand
RU2844753C2 (ru) Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения
HK40020170A (en) Bispecific t cell activating antigen binding molecules
HK1244294B (en) Antigen binding molecules comprising a trimeric tnf family ligand
HK1244294A1 (en) Antigen binding molecules comprising a trimeric tnf family ligand

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220302